Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan
Bone · 2026
DOI: 10.1016/j.bone.2026.118053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2026. Verfasst von Maria Bilal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Westmead Hospital, Darcy Rd, Westmead, NSW, 2145, Australia; Kolling Institute, Faculty of Medicine and Health, Universi…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Familial Hypophosphatemic Rickets. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
X-linked hypophosphataemia (XLH) is a rare, lifelong heritable metabolic bone disorder characterized by fibroblast growth factor 23 (FGF23) excess, chronic hypophosphataemia, renal phosphate wasting, progressive skeletal deformities and impaired quality of life. Burosumab, targeted anti-FGF-23 therapy, is approved for use in XLH across the lifespan. Clinical trials have demonstrated benefit, although distinct outcomes in response to treatment vary depending on whether initiated during childhood, adolescence or adulthood. We uniquely describe three patients with XLH across three generations within a single family, each initiated on burosumab at different stages of life. This familial case study highlights the broad phenotypic spectrum of XLH, and differential efficacy profile of burosumab across various stages, such as pre- and post-growth plate closure or in the presence of established musculoskeletal morbidity. We also demonstrate the unique inter-generational impact of burosumab in XLH, as a targeted novel treatment available for patients with a dominantly inherited disorder across the lifespan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Westmead Hospital, Darcy Rd, Westmead, NSW, 2145, Australia; Kolling Institute, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW, 2065, Australia. Electronic address: m…
- Department of Endocrinology, Westmead Hospital, Darcy Rd, Westmead, NSW, 2145, Australia; Kolling Institute, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW, 2065, Australia.
- The Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales, 2145, Australia; Discipline of Paediatrics and Child Health, The University of Sydney, New South Wales, 2006, Australia.
- Department of Endocrinology, Westmead Hospital, Darcy Rd, Westmead, NSW, 2145, Australia; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, 2006, NSW, Australia.
Zitieren
APA
Bilal, M., Kumar, S., Poon, M., Kim, A., & Girgis, C. M. (2026). Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan. Bone. https://doi.org/10.1016/j.bone.2026.118053
Vancouver
Bilal M, Kumar S, Poon M, Kim A, Girgis CM. Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan. Bone. 2026. doi:10.1016/j.bone.2026.118053
BibTeX
@article{Bilal2026,
author = {Bilal, Maria and Kumar, Shejil and Poon, Myra and Kim, Albert and Girgis, Christian M},
title = {Three Generations of X-Linked Hypophosphataemia: The Inter-generational Impact of Burosumab Across the Lifespan},
journal = {Bone},
year = {2026},
doi = {10.1016/j.bone.2026.118053}
}
EUVIMED